1. Home
  2. QTRX vs IPHA Comparison

QTRX vs IPHA Comparison

Compare QTRX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quanterix Corporation

QTRX

Quanterix Corporation

HOLD

Current Price

$3.53

Market Cap

160.0M

Sector

Industrials

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.61

Market Cap

165.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QTRX
IPHA
Founded
2007
1999
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
160.0M
165.3M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
QTRX
IPHA
Price
$3.53
$1.61
Analyst Decision
Hold
Strong Buy
Analyst Count
3
3
Target Price
$3.00
★ $6.67
AVG Volume (30 Days)
★ 904.7K
47.7K
Earning Date
11-09-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $37,632,000.00
N/A
Revenue This Year
$3.55
$390.56
Revenue Next Year
$10.02
$143.06
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 64.52
N/A
52 Week Low
$2.15
$1.18
52 Week High
$8.77
$2.71

Technical Indicators

Market Signals
Indicator
QTRX
IPHA
Relative Strength Index (RSI) 58.17 29.14
Support Level $3.31 $1.34
Resistance Level $3.74 $1.57
Average True Range (ATR) 0.26 0.12
MACD 0.07 -0.03
Stochastic Oscillator 64.39 1.49

Price Performance

Historical Comparison
QTRX
IPHA

About QTRX Quanterix Corporation

Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: